|
1 Indications And Usage Bosulif Is Indicated For The Treatment Of Adult Patients With: Newly-Diagnosed Chronic Phase (Cp) Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph+ Cml). This Indication Is Approved Under Accelerated Approval Based On Molecular And Cytogenetic Response Rates [See Clinical Studies (14.1) ] . Continued Approval For This Indication May Be Contingent Upon Verification And Confirmation Of Clinical Benefit In An Ongoing Long-Term Follow Up Trial. Chronic Phase, Accelerated Phase (Ap), Or Blast Phase (Bp) Ph+ Cml With Resistance Or Intolerance To Prior Therapy. Bosulif Is A Kinase Inhibitor Indicated For The Treatment Of Adult Patients With Newly-Diagnosed Chronic Phase Ph+ Chronic Myelogenous Leukemia (Cml). This Indication Is Approved Under Accelerated Approval Based On Molecular And Cytogenetic Response Rates. Continued Approval For This Indication May Be Contingent Upon Verification And Confirmation Of Clinical Benefit In An Ongoing Long-Term Follow Up Trial. ( 1 , 14 ) Chronic, Accelerated, Or Blast Phase Ph+ Cml With Resistance Or Intolerance To Prior Therapy. ( 1 )
|